Patients who take Vascepa (icosapent ethyl) and niacin together may face increased risk of bleeding due to the combination of both therapies causing a prolongation of bleeding time [1].
Icosapent ethyl, a highly purified eicosapentaenoic acid, is used to reduce the risk of cardiovascular events in patients with very high triglyceride levels. While it has been shown to provide benefits when used alone, combining it with niacin may amplify its effects on bleeding risk.
Data from drug patent databases indicates that Vascepa is available under a different name and in various other formulations, indicating its versatility in treatment options [2]. However, when used with niacin, patients should closely monitor their bleeding risk. Niacin therapy may independently also prolong bleeding time and interact with other drugs, heightening this risk when combined [3].
As such, health professionals must weigh potential benefits against these increased risks when recommending therapy for patients with severe high triglyceride levels. Patients should inform their healthcare providers about all medications, including any vitamins and supplements, that they are taking.
Sources:
[1] DrugPatentWatch.com, https://www.drugpatentwatch.com/drug/VAE-101-001-vascepa
[2] DrugPatentWatch.com, https://www.drugpatentwatch.com/drugs/vascepa
[3] DrugPatentWatch.com, https://www.drugpatentwatch.com/drugs/niacin